Abstract: The present invention provides methods of using a microbe containing a polypeptide that degrades, preferably detoxifies, a compound that is present in the environment. Preferably, the polypeptide is a hydrolase and the compound is at least one s-triazine. The present invention also provides a microbe containing a polypeptide that degrades, preferably detoxifies, a compound that is present in the environment.

Abstract: Disclosed are catalytic antibodies and polypeptides capable of degrading cocaine. Said catalytic antibodies and polypeptides are characterized by the amino acid sequence of their complementary determining regions and framework regions. The present invention also discloses a pharmaceutical composition and a method for decreasing the concentration and a method for decreasing the concentration of cocaine of a subject. Finally, the invention discloses pharmaceutical compositions and methods for treating cocaine overdose and addiction in subjects.

Abstract: The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.

Abstract: The invention provides isolated nucleic acids molecules, designated 57316 or 33338 nucleic acid molecules, which encode ubiquitin carboxyl terminal hydrolase proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57316 or 33338 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 57316 or 33338 gene has been introduced or disrupted. The invention still further provides isolated 57316 or 33338 proteins, fusion proteins, antigenic peptides and anti-57316 or 33338 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the proteins of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the proteins of the present invention, and methods of identifying modulators of the proteins of the present invention.

Abstract: Novel enterokinase cleavage sequences are provided. Also disclosed are methods for the rapid isolation of a protein of interest present in a fusion protein construct including a novel enterokinase cleavage sequence of the present invention and a ligand recognition sequence for capturing the fusion construct on a solid substrate. Preferred embodiments of the present invention show rates of cleavage up to thirty times that of the known enterokinase cleavage substrate (Asp)4-Lys-Ile.

Abstract: A method is provided for identifying a restriction endonuclease, which includes the steps of (a) screening a target DNA sequence for the presence of known methylase sequence motifs, (b) identifying any open reading frames which lie close to the methylase sequence motifs screened in step (a), and (c) assaying the protein products of these open reading frames for restriction endonuclease activity. Methods for identifying isoschizomers of known restriction endonucleases, which isoschizomers possess a desired physical property, such as thermostability, are also provided by the present invention, as are several novel restriction endonucleases isolated from M. jannaschii, MjaIII and MjaIV. Additionally, a gene was identified that encoded a previously observed endonuclease activity, designated MjaII. Also provided by the present invention are vectors suitable for cloning a DNA sequence encoding a cytotoxic protein, via independent transcription promotors which may be selectively controlled by several conditions.

Abstract: The heterologous expression of the reverse transcriptase from the Avian Myeloblastosis Virus (AMV-RT) in prokaryotic cells and in particular Escherichia coli (E. coli) is described in the present invention. The invention also includes certain measures to simplify the purification of the heterodimeric AMV-RT.

Abstract: The invention provides isolated nucleic acids molecules, designated 68999 nucleic acid molecules, which encode ubiquitin carboxyl-terminal hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 68999 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 68999 gene has been introduced or disrupted. The invention still further provides isolated 68999 proteins, fusion proteins, antigenic peptides and anti-68999 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: A process for producing a polynucleotide encoding a restriction endonuclease with an altered specificity, which process comprises: (a) mutagenising a polynucleotide encoding a restriction endonuclease with specificity for a recognition sequence so as to produce one or more mutated polynucleotides; and (b) isolating therefrom a polynucleotide encoding a mutated restriction endonuclease with specificity for an altered recognition sequence by selecting a polynucleotide which expresses a restriction endonuclease with methylase specificity for the altered recognition sequence.

Abstract: The present invention relates to a new use of uridine diphosphate glucose 4-epimerase (also called uridine diphosphate galactose 4-epimerase), and a method of converting uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) to uridine diphosphate N-acetylgalactosamine (UDP-GalNAc) by using the said enzyme. The process for producing UDP-GalNAc by using the uridine diphosphate glucose 4-epimerase and the UDP-GalNAc supply system according to the present invention are practical and efficient, and greatly beneficial to the industries.

Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.

Abstract: There are disclosed a protein having an amino acid sequence shown in SEQ ID NO:2, or a protein having a glutaminase activity in which one or more amino acids is/are deleted from, substituted by, inserted to or added to the amino acid sequence of the above protein; a gene containing DNA encoding the above protein or a gene which hybridizes with the a complementary sequence of DNA of the above gene under a stringent condition and encodes a protein having a glutaminase activity; a recombinant DNA containing the above gene; a transformant or a transductant containing the above recombinant DNA; and a process for producing glutaminase which comprises culturing the above transformant or the above transductant and collecting glutaminase from a culture medium.

Abstract: A method for controlling and modifying biopolymer synthesis by manipulation of the genetics and enzymology of synthesis of polyhydroxybutyrate (PHB) and polyhydroxyalkanoate (PHA) polyesters at the molecular level in procaryotic and eukaryotic cells, especially plants. Examples demonstrate the isolation, characterization, and expression of the genes involved in the production of PHB and PHA polymers. Genes encoding the enzymes in the PHB and PHA synthetic pathway (beta-ketothiolase, acetoacetyl-CoA reductase and PHB polymerise or PHA polymerase) from Zooloea ramigera strain I-16-M, Alcaligenes eutrophus, Nocardia salmonicolur, and Psuedomnas olevarans were identified or isolated and expressed in a non-PHB producing organism, E. coli. Specific modifications to the polymers include variation in the chain length of the polymers and incorporation of different monomers into the polymers to produce co-polymers with different physical properties.

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the drug-metabolizing enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the drug-metabolizing enzyme peptides, and methods of identifying modulators of the drug-metabolizing enzyme peptides.

Abstract: The invention provides human hydrolytic enzymes (HYENZ) and polynucleotides which identify and encode HYENZ. The invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HYENZ.

Abstract: Disclosed are bispecific antibodies comprising a first antibody binding specificity which confers the ability of the bispecific antibody to cross the blood-brain barrier, and a second antibody specificity conferring the ability of the bispecific antibody to bind to a ?-amyloid epitope. Also disclosed are methods for inhibiting the formation of ?-amyloid plaques in the brain of a human, of promoting the disaggregation of a preformed ?-amyloid plaque. Such methods recite the administration of a bispecific antibody.

Abstract: There is provided a method for sterilizing a transformed microorganism, which is characterized by mixing at a temperature range of 25° C. or higher to less than 35° C. a solution containing a transformed microorganism belonging to Escherichia introduced with a DNA coding for an enzyme having a thermal denaturation temperature of 50° C. or higher, with at least one member selected from the group consisting of monovalent alcohols having one to three carbon atoms and acetone, in an amount of 10 to 35% by weight of the solution.

Abstract: The present invention relates to recombinant DNA encoding the BsrGI restriction endonuclease as well as BsrGI methyltransferase, expression of BsrGI restriction endonuclease and BsrGI methyltransferase in E. coli cells containing the recombinant DNA.

Abstract: Novel human polynucleotide and polypeptide sequences are disclosed that can be used in industrial, therapeutic, diagnostic, and pharmacogenomic applications.